Keryx Biopharmaceuticals announces positive results from Zerenex study
Nov 30, 2010 6:09:00 AM
Keryx Biopharmaceuticals announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex, the company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. ?In this study, conducted pursuant to a Special Protocol Assessment with the FDA, Zerenex met the study's primary endpoint, described below, demonstrating a highly statistically significant dose response.?In addition, key secondary endpoints were also met with high statistical significance
